MassMutual Private Wealth & Trust FSB Has $65,000 Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

MassMutual Private Wealth & Trust FSB increased its position in DexCom, Inc. (NASDAQ:DXCM) by 46.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 833 shares of the medical device company’s stock after buying an additional 265 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in DexCom were worth $65,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in DXCM. Public Sector Pension Investment Board grew its position in shares of DexCom by 96.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 16,842 shares of the medical device company’s stock valued at $1,910,000 after buying an additional 8,261 shares during the last quarter. Toronto Dominion Bank increased its position in DexCom by 67.8% during the 2nd quarter. Toronto Dominion Bank now owns 198,295 shares of the medical device company’s stock valued at $22,483,000 after purchasing an additional 80,129 shares during the period. Armistice Capital LLC bought a new position in DexCom during the 2nd quarter worth approximately $944,000. APG Asset Management N.V. lifted its position in shares of DexCom by 5.9% in the 2nd quarter. APG Asset Management N.V. now owns 309,500 shares of the medical device company’s stock worth $32,742,000 after purchasing an additional 17,302 shares during the period. Finally, MBB Public Markets I LLC bought a new stake in shares of DexCom in the 2nd quarter valued at $3,151,000. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.2 %

Shares of NASDAQ DXCM opened at $88.75 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a market capitalization of $34.67 billion, a P/E ratio of 53.14, a P/E/G ratio of 2.23 and a beta of 1.12. The company has a 50-day moving average price of $79.25 and a 200-day moving average price of $77.51.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on DXCM. Canaccord Genuity Group lifted their target price on shares of DexCom from $89.00 to $99.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Citigroup lifted their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and upped their target price for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Raymond James decreased their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $99.29.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.